(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 March 2018 (08.03.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/041838 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/30* (2006.01)
A61K 35/761 (2015.01) *C07K 16/40* (2006.01)
C07K 16/28 (2006.01) *C12N 15/861* (2006.01)

(21) International Application Number:
PCT/EP2017/071674

(22) International Filing Date:
29 August 2017 (29.08.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

1614607.8	29 August 2016 (29.08.2016)	GB
1700663.6	13 January 2017 (13.01.2017)	GB
1706219.1	19 April 2017 (19.04.2017)	GB
1713765.4	28 August 2017 (28.08.2017)	GB

(71) Applicant: **PSIOXUS THERAPEUTICS LIMITED** [GB/GB]; PsiOxus House, 4-10 The Quadrant, Abingdon, Oxfordshire OX14 3YS (GB).

(72) Inventors: **CHAMPION, Brian, Robert**; PsiOxus Therapeutics Ltd, PsiOxus House, 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB). **BROWN, Alice, Claire, Noel**; PsiOxus Therapeutics Ltd, PsiOxus House, 4-10 The Quadrant, Barton Lane, Abingdon, Oxfordshire OX14 3YS (GB). **FREEDMAN, Joshua, David**; 83 Manor Road, Chigwell IG7 5PH (GB). **FISHER, Kerry, David**; 11 Cassington Road Eynsham, Witney OX29 4LH (GB). **SEYMOUR, Leonard, William**; 5 Workhouse Yard Chapel Hill, Wootton by Woodstock OX20 1YD (GB).

(74) Agent: **STERLING IP LTD**; Orion House Bessemer Road, Welwyn Garden City, United Kingdom AL7 1HH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER (BITE)

Figure 31



(57) Abstract: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE) comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.

[Continued on next page]

WO 2018/041838 A1

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*